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Abstract
Background—Poorly controlled cardiovascular risk factors are common. Evaluating whether
physicians respond appropriately to poor risk factor control in patients may better reflect quality of
care than measuring proportions of patients whose conditions are controlled.
Objectives—To evaluate therapy modifications in response to poor control of hypertension,
dyslipidemia, or diabetes in a large clinical population.
Design—Retrospective cohort study within an 18-month period in 2002 to 2003.
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Setting—Kaiser Permanente of Northern California.
Patients—253 238 adult members with poor control of 1 or more of these conditions.
Measurements—The authors assessed the proportion of patients with poor control who
experienced a change in pharmacotherapy within 6 months, and they defined “appropriate care” as
a therapy modification or return to control without therapy modification within 6 months.
Results—A total of 64% of patients experienced modifications in therapy for poorly controlled
systolic blood pressure, 71% for poorly controlled diastolic blood pressure, 56% for poorly controlled
low-density lipoprotein cholesterol level, and 66% for poorly controlled hemoglobin A1c level. Most
frequent modifications were increases in number of drug classes (from 70% to 84%) and increased
dosage (from 15% to 40%). An additional 7% to 11% of those with poorly controlled blood pressure,
but only 3% to 4% of those with elevated low-density lipoprotein cholesterol level or hemoglobin
A1c level, returned to control without therapy modification. Patients with more than 1 of the 3
conditions, higher baseline values, and target organ damage were more likely to receive “appropriate
care.”
Limitations—Patient preferences and suboptimal adherence to therapy were not measured and may
explain some failures to act.
Conclusions—As an additional measure of the quality of care, measuring therapy modifications
in response to poor control in a large population is feasible. Many patients with poorly controlled
hypertension, dyslipidemia, or diabetes had their therapy modified and, thus, seemed to receive
clinically “appropriate care” with this new quality measure.
Despite strong evidence that pharmacotherapeutic interventions contribute to preventing
cardiovascular events in high-risk individuals (1-5), risk factor control remains suboptimal
(6-9) and medications to reduce risk factors seem to be underused (10,11). Underuse of
evidence-based medications in chronic disease care may be partly due to “clinical
inertia” (12) by physicians and health care systems. As such, it represents a possible avenue
for quality improvement in health care (13,14).
The Health Plan Employer Data and Information Set (HEDIS) has developed measures to
assess health plan and individual physician performance (15) that are based directly on the
proportions of high-risk patients whose low-density lipoprotein (LDL) cholesterol levels,
hemoglobin A1c levels, and blood pressure are in control. Although such measures may identify
important deficiencies in quality (16) and are directly related to the health status of patients,
they may be confounded by population differences in case mix and therefore cannot distinguish
between a patient who is receiving poor care and a patient who is being appropriately treated
but who either does not adhere to treatment recommendations or has particularly severe disease
that is less responsive to treatment (17). Ideally, quality measures should reflect whether
physicians and systems deliver appropriate or optimal care. Provider responses to poorly
controlled risk factor levels, such as intensification of either behavioral therapy or
pharmacotherapy, have recently been proposed as “tightly linked” process indicators of quality.
Solid evidence suggests that these processes of care are directly linked to improved patient
outcomes (18,19). Such “tightly linked” process measures might be more clinically relevant
than the levels of either testing or control (18). Higher testing rates have not been shown to be
associated with better clinical control (7,19). To better understand the potential utility and the
feasibility of measuring therapy modifications in response to poor risk factor control as an
additional measure of quality, we examined the frequency and predictors of therapy
modifications in response to poorly controlled hyper-tension, dyslipidemia, and diabetes in a
large managed care population.
Context
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What actions do health care providers take for patients with poorly controlled cardiovascular
risk factors?
Content
This large retrospective cohort study from Kaiser Permanente of Northern California found
that, within a 6-month period, most patients received therapy modifications for the
following poorly controlled risk factors: systolic blood pressure (64%), diastolic blood
pressure (71%), low-density lipoprotein cholesterol level (56%), and hemoglobin A1c level
(66%). The most frequent modifications were adding drugs and increasing dosages.
Cautions
We do not know how often patient preferences or suboptimal adherence influenced
treatment decisions. The study did not directly link therapy modifications to clinical
outcomes.
—The Editors
METHODS
Study Participants
Description of the Study Population—We performed a retrospective cohort study within
an 18-month period from 1 July 2002 to 31 December 2003 of all members of Kaiser
Permanente Medical Care Program of Northern California who were older than 20 years of
age. Kaiser Permanente Medical Care Program is a fully integrated health care delivery system
that provides comprehensive medical care to more than 3 million members. Members comprise
approximately 30% of the northern California population and are demographically
representative of the population (20).
Primary care physicians, who worked with specialty care, health education, and nutrition
education staff located in close proximity, followed most patients. Many primary care teams
included care managers and either nurses or pharmacists, to whom patients with poor control
could be directly referred. All services were covered benefits.
Diagnostic Criteria—We searched clinical databases, including inpatient and ambulatory
diagnoses, ambulatory blood pressure measurements, laboratory results, and prescriptions for
the 18-month period before 31 December 2003, to identify all patients categorized as having
hypertension, dyslipidemia, diabetes mellitus, or a combination of these conditions and to
assess modifications in therapy in response to poor control. Criteria used to identify each
condition (Appendix Table 1, available at www.annals.org) have been described previously
(21). Previous studies have documented the accuracy of the clinical databases used in our study
for several diagnoses, including diabetes, coronary artery disease (CAD), and stroke (22, 23).
Diabetes diagnoses, myocardial infarction, and stroke are confirmed at chart review in 98%,
99%, and 75% of cases, respectively.
Study Cohort—To assess therapy modifications in response to poorly controlled
hypertension, dyslipidemia, or diabetes mellitus, we identified patients who met criteria for
poor control of 1 condition or more at some point during the study period. Appendix Table 2
(available at www.annals.org) details our definitions of poor control. We did not include
patients with moderately elevated risk factors because initial lifestyle modification is often
appropriate for these participants (4, 5), so pharmacotherapeutic interventions may not be
warranted. To allow a complete 6-month follow-up, we extended observation into 2004 for
those whose poor control was first identified in the second half of 2003. We excluded members
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who were not continuously enrolled 4 months before and 6 months after the date of the defining
measure of poor control because we did not have adequate time for observation (Figure). We
also excluded patients with diabetes who were already treated with insulin therapy, because
day-to-day adjustments in insulin dosage cannot be reliably identified from automated data
sources.
Measurements
Therapy Modifications in Response to Poor Control—On the basis of previous
definitions of “tightly linked” quality measures (17), we defined a potential therapy
modification as an increase in the number of drug classes, increased dosage of 1 medication
or more, or a switch to another medication in a different therapeutic class. We did not treat
switches to medications in the same therapeutic class as a therapy modification, unless the
daily dose of the new agent represented an increase in bioequivalent dose compared with the
previous agent, because a switch could be in response to side effects rather than an
intensification of therapy. Other outcomes included a return to control without therapy
modification, which was based on the last risk factor measurement recorded during the 6-month
period; a return to “near control” (Appendix Table 2, available at www.annals.org); and no
therapy modification with either no return to control or no further measurement. This last
category included patients with no follow-up visit during the interval. Recognizing that
physicians may sometimes opt for nonpharmacologic recommendations for an elevated risk
factor value, we created an outcome called “appropriate care,” defined as either a therapy
modification or return to control without therapy modification within 6 months. We also
examined responses within 3 months.
Pharmacologic Management—We defined pharmacologic therapy from prescriptions
filled during the 4 months before and the 6 months after the first abnormal risk factor measure.
We grouped drugs by drug codes into therapeutic classes, with 7 classes for hypertension
(thiazide diuretics, other diuretics, β-blockers, calcium-channel blockers, angiotensin-
converting enzyme inhibitors, angiotensin-receptor blockers, and other antihypertensive
agents), 5 classes for dyslipidemia (statins, fibric acid derivatives, niacin, bile acid resins, and
other lipid-lowering agents), and 5 classes for diabetes mellitus (insulin, sulfonylureas,
metformin, thiazolidinediones, and other diabetes-related medications). We recorded daily
dosages and defined increased dosage as any increase in daily dose in milligrams. When drugs
from more than 1 medication class were taken, we considered a dosage increase for any class.
For patients who did not have therapy modifications, we assessed the proportion of patients
who may have already been receiving maximal therapy. We defined maximal therapy as
receiving 3 medications for hypertension or diabetes (including the proportion who were
receiving high doses of all 3 medications) or receiving a “maximal” dose of statin therapy (80
mg of simvastatin or ≥40 mg of atorvastatin). Combination lipid-lowering therapy was very
uncommon.
Covariates—We examined the relationship between several patient factors and receipt of
“appropriate care” in response to poor control, notably whether physicians responded
differently in relation to patients' level of cardiovascular risk as reflected by the presence of
several conditions or target organ disease. We defined 3 mutually exclusive categories of
cardiovascular risk: history of CAD, other target organ damage, and no history of either
condition. We defined previous CAD as any diagnosis of myocardial infarction, angina
pectoris, atherosclerotic heart disease, or coronary revascularization recorded during the
previous 5 years. We defined target organ damage on the basis of the definitions of the Sixth
Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure (JNC VI) (24): previous diagnoses of hypertensive heart disease,
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congestive heart failure, cerebrovascular or peripheral arterial disease, and nephropathy
(defined as renal failure or insufficiency during the previous 5 years or by a most recent serum
creatinine level greater than 124 μmol/L [>1.4 mg/dL] for women or greater than 133 μmol/L
[>1.5 mg/dL] for men). Race and ethnicity data were available for 76% of patients from
responses to previous member surveys and previous hospital discharges.
Statistical Analysis
For each condition, we determined the proportions of poorly controlled patients who
experienced each possible response described earlier. All 95% CIs were smaller than ± 1.0%
and are therefore not presented. We assessed independent patient factors associated with
“appropriate care” at 6 months (vs. “inappropriate care”) by using multivariable logistic
regression. To account for the clustered study design (patients clustered within 1570 physicians
within 17 medical centers), we used hierarchical logistic regression models (SAS GLIMMIX
macro, SAS Institute, Inc., Cary, North Carolina), with medical center as a fixed factor and
physician as a random factor (25). Because logistic regression odds ratios become poor
estimates of relative risk when outcomes are common (26), we used predicted adjusted
proportions of patients receiving “appropriate care” and 95% CIs.
To examine variability in “appropriate care” among medical centers and physicians, we
calculated the interquartile ranges for the adjusted proportions from the regression models.
Because we treated medical center as a fixed effect, we could directly calculate adjusted
proportions. For physicians, we estimated the adjusted proportions by using the assumed
normal distribution with mean zero. To assess whether the inclusion of patients who returned
to control without therapy modification in the “appropriate care” category affected our
findings, we performed a sensitivity analysis that excluded those patients from the
multivariable models. Because of missing data on race or ethnicity (Table 1), we used complete
case analysis for the multivariate models, which is less subject to bias than treating observations
with missing race or ethnicity as a separate category (28). We conducted all analyses using
SAS, version 8 (SAS Institute, Inc., Cary, North Carolina).
Role of the Funding Source
The Pharmaceuticals Outcomes Research Group of Pfizer Inc. funded the data collection and
analysis. Investigators at Kaiser Permanente performed the analyses. By contract, the final
author (J.V. Selby) retains the right to publish the paper without approval from Pfizer Inc.
Kaiser Permanente's Institutional Review Board approved the study.
RESULTS
Population Characteristics and Degree of Control
Among 647 857 patients identified as having hypertension, dyslipidemia, diabetes mellitus, or
a combination of these conditions, 28% of those with hypertension, 42% of those with diabetes,
and 42% of those with dyslipidemia met criteria for poor control (Figure). By using the tighter
definitions of “in control” (Appendix Table 2, available at www.annals.org), we found that
55%, 55%, and 49% of patients, respectively, were not in control at the end of 2003.
Table 1 details the baseline demographic characteristics and comorbid conditions. Relatively
few patients received several medications at baseline and relatively small proportions of
patients were receiving maximal doses of any medication. Most of the 1570 physicians were
internists (64%) or family physicians (16%); other physicians' specialties were uncommon
(each < 3%). The mean number of patients per physician for each condition ranged from 18
patients (range, 1 patient to 85 patients) for diastolic blood pressure to 86 patients (range, 1
patient to 236 patients) for LDL cholesterol level.
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Therapy Modifications during 3-Month and 6-Month Periods
Among patients with poor control, 54% experienced therapy modifications for poorly
controlled systolic blood pressure within 3 months, 63% for poorly controlled diastolic blood
pressure, 47% for poorly controlled LDL cholesterol level, and 57% for poorly controlled
hemoglobin A1c level (Table 2). At 3 months, the most frequent modifications were increases
in the number of drug classes (from 62% to 84%) and increased dosage (from 14% to 37%).
With 3 further months of observation, the proportion of patients experiencing therapy
modifications increased to 64% for poorly controlled systolic blood pressure, 71% for diastolic
blood pressure, 56% for LDL cholesterol level, and 66% for hemoglobin A1c level.
Most patients (≥80%) had 1 therapy modification within 6 months, compared with those who
had several modifications. For all conditions, most patients (>70%) had a therapy modification
in the first 2 months after the elevated level for all conditions, and only 2% to 6% of
modifications occurred during the sixth month. Furthermore, 7% to 11% of those with poorly
controlled blood pressure, but only 3% to 4% of those with elevated LDL cholesterol level or
hemoglobin A1c level, returned to control without therapy modification. Thus, 71% to 82% of
all patients with poorly controlled blood pressure had “appropriate care,” defined as either a
therapy modification or a return to control. For elevated levels of LDL cholesterol and
hemoglobin A1c, 59% and 70% of patients had “appropriate care,” respectively.
Approximately 50% of patients with “inappropriate care” were not measured further in the
observation period. Among those with “inappropriate care,” 24% of those with poorly
controlled systolic blood pressure, 18% of those with poorly controlled diastolic blood
pressure, and 5% of those with poorly controlled hemoglobin A1c level were already receiving
3 or more medications at baseline, but only 0.6% to 1.5% of these patients were receiving high
doses of the 3 medications. Only 4% were already receiving a maximal dose of statins.
Factors Associated with “Appropriate Care”
Higher baseline values, co-occurrence of 1 or more of the 3 conditions, and previous CAD or
target organ damage were independently associated with “appropriate care” in response to poor
control at 6 months (Table 3). The main exceptions were that patients with diabetes were less
likely to have “appropriate care” in response to elevated systolic blood pressure and were not
more likely to have “appropriate care” in response to elevated hemoglobin A1c levels in the
presence of CAD or target organ damage. The effects of demographic characteristics varied
by condition. Women were more likely to have “appropriate care” in response to all poorly
controlled risk factors except for systolic blood pressure. Older age was associated with
“appropriate care” in response to poorly controlled diastolic blood pressure and LDL
cholesterol levels, and younger age was associated with “appropriate care” in response to
poorly controlled hemoglobin A1c level and systolic blood pressure.
In general, nonwhite patients (African-American, Asian, or Latino patients) were less likely
than white patients to have responses for hemoglobin A1c control but were slightly more likely
to have “appropriate care” in response to poor blood pressure control. Latino and Asian patients,
but not African-American patients, were more likely than white patients to have “appropriate
care” in response to poorly controlled LDL cholesterol levels. For other race or ethnicity
groups, most results were not statistically significant and had wide CIs.
Excluding the patients who returned to control without any therapy modification from the
multivariable models yielded similar results for all factors. We also evaluated the number of
medications that patients were taking for any other of the 3 conditions to see whether
medication burden may be a barrier to treatment modification. The number of these medications
did not decrease the likelihood of a therapy change for each condition. Its inclusion in the
Rodondi et al. Page 6
Ann Intern Med. Author manuscript; available in PMC 2008 November 3.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
multivariate models diminished the strength of cooccurrence of other conditions with the
outcomes. The variation in “appropriate care” was slightly larger at the physician level than at
the medical center level for all outcomes: from 66.8% to 75.1% (interquartile ranges) at the
physician level versus from 70.3% to 73.2% at the medical center level for systolic blood
pressure; 79.5% to 85.0% versus 81.1% to 84.5%, respectively, for diastolic blood pressure;
52.6% to 64.5% versus 55.9% to 61.1%, respectively, for dyslipidemia; and 64.7% to 74.2%
versus 67.4% to 70.6%, respectively, for diabetes.
DISCUSSION
In this large clinical population, many patients with poorly controlled hypertension,
dyslipidemia, or diabetes were receiving relatively few medications and relatively low doses
when poor control was first noted. For each condition, most patients received a therapy
modification within the following 6 months. Moreover, physicians were more likely to respond
to poor risk factor control when cardiovascular risk was higher. These data demonstrate that
measuring therapy modifications as possible markers of quality in a large patient population
is feasible. These “tightly linked” process measures (18,19) might represent an additional
opportunity for improving quality of care. They met an important criterion for utility as a quality
measure in that variation among physicians was substantial in each measure.
The frequency of therapy modifications in response to poorly controlled cardiovascular risk
factors was higher in our study than that in 2 previous studies using similar measures. In a
Veterans Affairs study in 1998 to 1999, 39% of 307 patients with diabetes and LDL cholesterol
levels of 3.4 mmol/L or greater (≥130 mg/dL) began or increased lipid-lowering medication
therapy within 6 months and 6% returned to control without a therapy modification (17). In a
study in 30 U.S. academic medical centers in 2000 to 2001, 14% of patients with diabetes and
untreated blood pressure greater than 150/100 mm Hg had therapy initiated, 15% of those
patients with untreated LDL cholesterol levels of 3.4 mmol/L or greater (≥130 mg/dL) had
therapy initiated, and 46% of patients with hemoglobin A1c levels of 8% or greater had
modifications in hypoglycemic therapy, but these changes were only assessed at 1 visit (19).
These studies were limited to patients with diabetes and had examined an earlier study period.
We observed that therapy modifications in response to poor control were more likely in the
presence of increased risk, as measured by co-occurrence of another of the 3 conditions, higher
baseline risk factor values, and presence of previous CAD or target organ damage. Recent
guidelines for control of both blood pressure and LDL cholesterol level emphasize tighter
control in patients who are at greatest cardiovascular risk (4,5), which is likely to have a greater
effect on preventing cardiovascular disease compared with treating low-risk patients.
For 18% to 41% of patients who were in poor control for 1 of these risk factors, we observed
no “appropriate care” within 6 months. These apparent failures to respond have several
potential explanations in addition to poor quality of care. Very small proportions of these
patients were already receiving maximal medical therapy. For these patients, physicians may
have been reluctant to further intensify therapy because of concerns over side effects. Patients'
lack of adherence to pharmacotherapy may undoubtedly explain some failures. In our
pharmacy data system, changes in pharmacotherapy are only observed if the patient fills the
new prescription. Missed appointments and missed laboratory tests would also lead to apparent
failures to respond. A previous study in this population demonstrated that the rate of missed
outpatient appointments was highly predictive of glycemic control among patients with
diabetes (29). Finally, physician choices to recommend lifestyle modification may also explain
some failures to respond. We could not identify such recommendations in our data. However,
we counted return to control within 6 months, which may have been due to successful lifestyle
modification, as “appropriate care.”
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Nevertheless, in view of the relatively low levels of treatment intensity at baseline, most
observed failures to change therapy are probably due to poor quality of care or clinical inertia
(12). Proposed explanations for clinical inertia include physicians' overestimation of their
adherence to guidelines (12) or acceptance of elevated risk factor levels in their patients (30),
lack of training on achieving therapeutic goals, possible lack of motivation in clinicians to treat
asymptomatic chronic conditions (12), pharmacotherapy pill burden (31), acute symptoms that
supersede risk factor management, and time limitations (32). Quality improvement strategies
that incorporate more clinically specific measures of “appropriate care,” such as those
examined in our study, into performance feedback or physician reminder systems (12) may be
more effective in overcoming these barriers and improving risk factor levels.
The rates of nonresponse differed between conditions, which might provide information on
the reasons for non-response. Similar to previous studies (33,34), therapy modifications were
more likely in response to poor control of diastolic than systolic blood pressure, possibly
reflecting a continued lack of awareness among physicians of the greater importance of systolic
blood pressure in predicting cardiovascular risk (34,35). The frequency of therapy
modifications was higher for poorly controlled blood pressure than for diabetes and particularly
for dyslipidemia, possibly because more drug classes are available for hypertension. For
diabetes, concerns about hypoglycemia and patient or physician reluctance to initiate insulin
therapy may be specific additional barriers to the implementation of more intensive control
(36,37). Moreover, contraindications for therapies may further restrict therapeutic options. As
patients got older, physicians were less likely to intensify treatment for poorly controlled
systolic blood pressure and hemoglobin A1c level, possibly reflecting a greater concern about
treatment side effects, pill burden, or adherence to therapy.
An intriguing finding is the variation in response by patient race or ethnicity across the 3
conditions. These differences were small but persisted after adjustment for factors associated
with higher cardiovascular risk and demographic characteristics. Our data suggest that a lower
likelihood of therapy modifications in response to elevated hemoglobin A1c levels may explain
the poorer glycemic control that have been widely found in nonwhite patients with diabetes in
the United States (22,38). Higher therapy modification rates in nonwhite patients for poorly
controlled hypertension and LDL cholesterol levels have not been noted previously and should
be further explored.
Our study has several limitations and remaining questions. Our data do not permit identification
of many causes of nonresponse to poor control that were discussed earlier. Thus, optimal rates
of therapy intensification are unknown and are certainly less than 100%. Although our analyses
do not directly demonstrate that therapy modifications led to better control, their validity is
indirectly supported by the several randomized, controlled trials that have demonstrated the
efficacy of these pharmacotherapeutic interventions (1-5). Several previous studies have also
shown that clinical inertia was associated with poor risk factor control (12,39) and
intensification of therapy with better control (17,39-41). A final validation would examine
whether higher rates of treatment intensification or “appropriate care” are associated with better
levels of control across populations or over time. This was beyond the scope of our study. Our
measure for diabetes is not currently applicable to patients who are already receiving insulin
because day-to-day adjustments in insulin dosage are not available in automated data sources.
Finally, therapy changes for hypertension might have been modestly misclassified if these
drugs were prescribed primarily for reasons other than hypertension. However, these drugs
were introduced in the 6 months after an elevated risk factor value, and the timing of the changes
(>70% during the first 2 months) suggests that most changes were related to the elevated risk
factor value. Even if drugs were prescribed primarily for a condition other than hypertension,
the medication may help to lower blood pressure. We also could not assess whether the total
number of medications was inversely related to the likelihood of a change in therapy because
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our data set did not include noncardiovascular medications, but we found that the total number
of medications taken for any other of the 3 conditions did not decrease the likelihood of a
change in therapy.
We believe that our study is the first to demonstrate the feasibility of assessing “tightly linked”
measures in a large patient population, which should generalize to other health care
organizations with electronic clinical databases (18). Such measures have been proposed to
have several advantages over simpler process measures, such as rates of risk factor testing, and
also over levels of control. Intensification of therapy, but not higher testing rates for risk factors
(7,19), has been shown to lead to better control (17,39-41). For example, a study in 30 U.S.
academic medical centers found a very high proportion of testing rates (88% to 97%) for
cardiovascular risk factors in patients with diabetes, but a low proportion of patients in control
(33% to 46%) and a low rate of therapy modifications in those with elevated risk factor levels
(14% to 46%) (19). Unlike measurements of risk factor control, measures of treatment
intensification are directly actionable by physicians or by systems (18). These process-of-care
measures do not penalize physicians or systems that care for sicker or less adherent patients
(42). Hofer and colleagues (43) showed that high outlier physicians could dramatically improve
profiles on the basis of levels of control alone, simply by avoiding caring for some patients
with elevated risk factor levels.
However, the measure we examined considers only patients with poorly controlled risk factors
and could not, therefore, be the only quality indicator for a condition. An assessment of overall
quality must consider both the proportions of patients with the condition who are in control
and the clinician behavior in response to those who are not. Future studies should assess
whether reporting performance that is partly based on this new measure would be more
clinically relevant and acceptable to physicians than simply reporting levels of testing or control
and would improve risk factor control.
In summary, we have demonstrated that therapy modifications in response to poor risk factor
control can be measured as an additional marker of quality in a large patient population. Most
patients with poor control of hypertension, dyslipidemia, and diabetes experienced a therapy
modification within 6 months. Because appropriate physician response to poor control is a
critical intermediate step between risk factor assessment and clinical outcomes (18), inclusion
of such responses, in conjunction with standard assessments of proportions of patients who are
already in control, may provide a more accurate index of the quality of clinical care than relying
solely on measures of proportions of patients who are in control. It may lead to improved control
of risk factors.
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Appendix Table 1
Diagnostic Criteria for Diabetes Mellitus, Hypertension, and Dyslipidemia*
Condition Diagnostic Criteria
Diabetes mellitus At least 1 prescription of insulin or an oral hypoglycemic agent; at least 2 outpatient diagnoses of diabetes mellitus; 1
outpatient diagnosis of diabetes mellitus plus at least 1 hemoglobin A1c measurement ≥ 7%; or at least 1 hospital discharge
with a primary diabetes mellitus–related diagnosis (ICD-9 code 250.X)
Hypertension At least 1 prescription for an antihypertensive medication plus an outpatient diagnosis of hypertension; at least 2 outpatient
diagnoses of hypertension; at least 1 prescription for an antihypertensive medication plus at least 1 elevated outpatient
blood pressure reading (≥140 mm Hg [systolic] or ≥90 mm Hg [diastolic]); or at least 1 outpatient diagnosis of hypertension
plus at least 1 blood pressure reading of ≥140 mm Hg (systolic) or ≥ 90 mm Hg (diastolic)
Dyslipidemia At least 1 prescription for an antilipemic agent or outpatient diagnosis of hyperlipidemia or hypercholesterolemia with a
previous LDL cholesterol value ≥ risk-appropriate cut-point value, as defined in Appendix Table 2
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Condition Diagnostic Criteria
*
ICD-9 = International Classification of Diseases, Ninth Revision; LDL = low-density lipoprotein.
Appendix Table 2
Levels of Control for Hypertension, Dyslipidemia, and Diabetes Mellitus*
Condition Measure In Control Near Control Poor Control
Hypertension
 No diabetes mellitus and no
target organ disease
2 consecutive SBP <140 mm Hg 140–159 mm Hg ≥160 mm Hg
2 consecutive DBP <90 mm Hg 90–99 mm Hg ≥100 mm Hg
 With diabetes mellitus or
target organ disease
2 consecutive SBP <130 mm Hg 130–139 mm Hg ≥140 mm Hg
2 consecutive DBP <85 mm Hg 85–89 mm Hg ≥90 mm Hg
Dyslipidemia
 Low risk
  No diabetes mellitus or
CAD, <2 CAD risk factors
LDL cholesterol level <4.2 mmol/L (<160
mg/dL)
4.2–4.9 mmol/L (160–
189 mg/dL)
≥5.0 mmol/L (≥190
mg/dL)
 Moderate risk
  2 CAD risk factors but 10-
y Framingham risk score <
20%
LDL cholesterol level <3.4 mmol/L (<130
mg/dL)
3.4–4.1 mmol/L (130–
159 mg/dL)
≥4.2 mmol/L (≥160
mg/dL)
 High risk
  ≥ 2 CAD risk factors and
10-y Framingham risk score ≥
20%
LDL cholesterol level <2.6 mmol/L (<100
mg/dL)
2.6–3.3 mmol/L (100–
129 mg/dL)
≥3.4 mmol/L (≥130
mg/dL)
  With diabetes mellitus or
previous CAD
LDL cholesterol level <2.6 mmol/L (<100
mg/dL)
2.6–3.3 mmol/L (100–
129 mg/dL)
≥3.4 mmol/L (≥130
mg/dL)
Diabetes mellitus Hemoglobin A1c <7.0% 7.0%–7.9% ≥8.0%
*
CAD = coronary artery disease; DBP = diastolic blood pressure; LDL = low-density lipoprotein; SBP = systolic blood pressure.
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Figure.
Flow of participants in the study.
Levels of control and poor control for each condition are defined in Appendix Table 2 (available
at www.annals.org). Poor control of blood pressure (BP) is defined as poor control of systolic
blood pressure, diastolic blood pressure, or both. LDL = low-density lipoprotein. *Exclusion
of patients who were not continuously enrolled 4 months before and 6 months after the date
with abnormal value.
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Table 1
Baseline Characteristics of 253 238 Patients with Poorly Controlled Hypertension, Dyslipidemia, and Diabetes Mellitus
Characteristic Patients with Poorly Controlled
Hypertension
Patients with
Poorly Controlled
Dyslipidemia (n =
132 266)
Patients with
Poorly
Controlled
Diabetes
Mellitus (n = 48
568)
Systolic Blood
Pressure (n =
125 427)
Diastolic Blood
Pressure (n =
31 121)
Demographic
 Mean age, y 67.3 57.7 61.7 58.1
 Age, %
  20–44 y  4.8 16.3  8.0 13.5
  45–64 y 34.6 53.3 50.3 56.2
  ≥65 y 60.6 30.4 41.7 30.4
 Women, % 58.1 48.0 49.4 44.3
 Race or ethnicity, %
  White 53.6 41.5 47.5 34.4
  African American 10.5 14.4  7.8  9.6
  Asian  8.0  7.7  9.2 12.3
  Latino  6.3  5.1  6.0 10.7
  Mixed  3.0  3.0  2.5  3.6
  Native American  0.6  0.6  0.5  0.7
  Pacific Islander  0.1  0.1  0.1  0.2
  Missing data 17.8 27.6 26.5 28.5
Comorbid conditions, %
 Coronary artery disease 27.7 19.2 20.7 16.6
 Other target organ damage 53.0 46.9 28.2 37.0
  Cerebrovascular disease 19.7 14.7 10.3  9.0
  Peripheral arterial disease 13.0  7.8  6.8  8.6
  Nephropathy 29.3 27.5 15.3 25.9
  Other disease* 16.7 14.1  7.9  8.9
 Co-occurrence of the 3 conditions
  Hypertension only 32.1 38.8 – –
  Dyslipidemia only  –  – 22.9  –
  Diabetes mellitus only  –  –  – 13.3
  Hypertension and dyslipidemia 26.8 24.0 41.1  –
  Hypertension and diabetes mellitus 10.4 11.3  – 16.7
  Dyslipidemia and diabetes mellitus  –  –  9.3 17.4
  All 3 conditions 30.7 25.9 26.7 52.6
Baseline medications, %
 Medications for each condition
  0 medication 20.2 25.9 72.6 34.6
  1 medication 29.4 30.1 26.0 35.9
  2 medications 27.4 24.5  1.4 25.9
  3 medications 16.4 13.7  0.0  3.6
  ≥4 medications  6.5  5.8  0.0  0.1
 Highest level of dosage if receiving
medications for each condition†
  Low 34.1 34.7 21.4 36.7
  Medium 31.3 31.2 56.6 21.1
  High 34.6 34.1 22.1 42.2
 Medications for others of the 3 conditions
  0 medication 46.6 55.4 34.1 27.1
  1 medication 30.3 26.4 21.4 23.6
  2 medications 13.7 11.0 21.2 19.2
  3 medications  7.2  5.6 12.9 15.6
  ≥4 medications  2.3  1.6 10.3 14.5
*
Other disease included hypertensive heart disease and heart failure.
†
In this table, daily dosages were categorized as low, medium, or high on the basis of inspection of dosage distributions for all users of each medication
and on the basis of recommendations of the Physicians' Desk Reference (27). When drugs from more than 1 medication class were taken, the highest
dosage of any class was considered.
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Table 2
Proportion of Patients with Poorly Controlled Hypertension, Dyslipidemia, or Diabetes Mellitus Who Had Subsequent
Therapy Modifications within a 3-Month and 6-Month Period*
Characteristic Patients with Poorly
Controlled Hypertension
(Systolic BP) (n = 125
427), %
Patients with Poorly
Controlled Hypertension
(Diastolic BP) (n = 31
121), %
Patients with Poorly
Controlled Dyslipidemia
(LDL Cholesterol) (n = 132
266), %
Patients with Poorly
Controlled Diabetes
Mellitus (Hemoglobin A1c)
(n = 48 568), %
3 Months 6 Months 3 Months 6 Months 3 Months 6 Months 3 Months 6 Months
“Appropriate care” 60.9 71.1 74.3 82.4 48.5 58.6 58.1 69.7
 Any therapy modification 54.3 64.3 62.7 71.1 47.0 55.8 57.0 66.2
  Increase in the number of drug
classes 61.8 70.3 65.5 73.3 84.2 83.5 70.1 73.7
  Increased dosage of ≥1
medication 36.6 39.9 33.7 37.1 13.9 15.3 29.7 34.0
  Switch to another medication
in a different class† 15.1  8.2 16.0  9.5  2.1  1.6  7.9  3.7
  Several therapy modifications 13.8 18.8 15.6 20.3  0.4  0.9  7.7 11.6
 Return to control without therapy
modification‡  6.6  6.8 11.6 11.3  1.5  2.8  1.1  3.5
“Inappropriate care” 39.1 28.8 25.7 17.6 51.5 41.4 41.9 30.3
 No therapy modification and
return to near control‡  7.8  7.7  4.1  3.6  3.2  6.2  3.0  5.7
 No therapy modification and no
return to control‡ 12.7 11.5  6.0  5.3  4.5  8.6  5.3  7.3
 No further measurement and no
therapy modification§ 18.6  9.6 15.6  8.7 43.8 26.6 33.6 17.3
*
Confidence intervals for all proportions in this table are narrower than ±1.0%. BP = blood pressure; LDL = low-density lipoprotein.
†
A switch to another medication in a different class was counted only when a new class of medication for the condition was added, but the total number
of drug classes remained the same.
‡
Levels of control and near control for each condition are defined in Appendix Table 2 (available at www.annals.org).
§
This category included those with no new visit or no new measurements.
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Table 3
Multivariable Analyses of Factors Associated with “Appropriate Care” in Response to Poorly Controlled Hypertension,
Dyslipidemia, and Diabetes Mellitus*
Characteristic Adjusted Proportions (95% CI), %
Poorly Controlled Hypertension Poorly Controlled
Dyslipidemia (n =
132 266)
Poorly Controlled
Diabetes Mellitus
(n = 48 568)
High Systolic BP
(n = 125 427)
High Diastolic BP
(n = 31 121)
Age
 20–44 y 71.2 (69.5–72.8)† 78.4 (76.7–80.1)† 54.4 (52.9–56.0)‡ 73.0 (71.2–74.7)‡
 45–54 y 71.5 (70.5–72.5)† 80.0 (78.9–81.1)† 57.9 (56.9–58.9)‡ 68.0 (66.8–69.2)‡
 55–64 y 69.9 (69.1–70.6)† 81.7 (80.7–82.7)† 58.6 (57.8–59.4)‡ 67.2 (66.1–68.2)‡
 ≥65 y 70.1 (69.5–70.6)† 85.5 (84.7–86.3)† 58.5 (57.8–59.2)‡ 68.0 (67.0–69.1)‡
Sex
 Women 69.3 (68.7–69.8) 83.7 (82.9–84.4) 58.8 (58.1–59.5) 69.6 (68.7–70.5)
 Men 71.6 (71.0–72.2)§ 80.7 (79.9–81.5)§ 57.6 (56.9–58.3)§ 66.9 (66.0–67.8)§
Race or ethnicity
 White 69.3 (68.8–69.8) 81.8 (81.0–82.6) 57.7 (57.1–58.4) 70.5 (69.6–71.4)
 African American 72.6 (71.6–73.5)§ 82.2 (80.9–83.4) 57.0 (55.8–58.2) 65.9 (64.2–67.5)§
 Asian 72.3 (71.3–73.3)§ 83.9 (82.3–85.4)∥ 60.8 (59.8–61.9)§ 66.0 (64.6–67.4)§
 Latino 71.6 (70.4–72.7)§ 83.0 (81.1–84.8) 59.4 (58.1–60.7)∥ 66.3 (64.8–67.7)§
 Mixed 70.1 (68.5–71.7) 82.3 (79.7–84.6) 58.7 (56.8–60.5) 66.2 (63.7–68.6)§
 Native American 70.8 (67.3–74.1) 83.1 (77.3–87.6) 57.7 (53.6–61.6) 63.5 (57.8–68.9)¶
 Pacific Islander 73.2 (61.8–82.2) 87.6 (63.2–96.7) 63.9 (52.4–74.0) 66.2 (55.7–75.4)
Co-occurrence of other conditions
 None 68.6 (67.9–69.3) 79.6 (78.6–80.6) 51.3 (50.4–52.3) 59.9 (58.0–61.7)
 Hypertension and dyslipidemia 71.6 (70.9–72.3)§ 83.4 (82.3–84.4)§ 54.3 (53.6–55.0)§ –
 Hypertension and diabetes mellitus 66.0 (64.9–67.0)§ 81.2 (79.6–82.8) – 66.3 (64.9–67.7)§
 Dyslipidemia and diabetes mellitus – – 66.9 (65.7–68.1)§ 66.6 (65.1–68.0)§
 All 3 conditions 72.1 (71.4–72.7)§ 85.1 (84.2–86.0)§ 66.5 (65.7–67.3)§ 70.7 (69.9–71.5)§
Risk status
 No target organ disease 70.0 (69.3–70.7) 80.4 (79.4–81.4) 54.2 (53.5–54.9) 69.1 (68.2–70.0)
 Target organ disease (not CAD) 70.1 (69.5–70.8) 83.2 (82.3–84.0)§ 60.5 (59.6–61.4)§ 67.5 (66.4–68.6)∥
 CAD 70.5 (69.8–71.2) 83.7 (82.5–84.7)§ 65.6 (64.8–66.4)§ 66.7 (65.4–68.0)¶
Baseline level of each condition
 Systolic BP
  140–159 mm Hg 65.3 (64.7–65.9)† – – –
  160–179 mm Hg 75.5 (74.9–76.1)† – – –
  ≥180 mm Hg 81.5 (80.7–82.3)† – – –
 Diastolic BP
  90–99 mm Hg – 79.5 (78.7–80.3)† – –
  100–109 mm Hg – 85.0 (84.1–85.8)† – –
  ≥110 mm Hg – 89.2 (87.8–90.4)† – –
 LDL cholesterol level
  3.4–4.1 mmol/L (130–159 mg/
dL) – – 50.4 (49.7–51.2)† –
  4.2–4.9 mmol/L (160–189 mg/
dL) – – 59.9 (59.1–60.6)† –
  ≥5.0 mmol/L (≥190 mg/dL) – – 72.6 (71.8–73.4)† –
 Hemoglobin A1c
  8.0%–8.9% – – – 61.8 (60.8–62.7)†
  9.0%–9.9% – – – 69.8 (68.6–71.0)†
  ≥10% – – – 78.1 (77.2–79.0)†
*
Hierarchical logistic regression with adjustment for all the covariates in this table. These multivariable models assessed patient factors associated with
“appropriate care” (vs. “inappropriate care”) at 6 months. “Appropriate care” was defined as therapy modifications or return to control without therapy
modification. BP = blood pressure; CAD = coronary artery disease; LDL = low-density lipoprotein.
†
P for trend < 0.001.
‡
P for trend < 0.05.
§
P < 0.001 compared with reference group.
∥
P < 0.05 compared with reference group.
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¶
P < 0.01 compared with reference group.
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